Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

  • ID: 3766756
  • Report
  • Region: Global
  • 49 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Naia Limited
  • Shire Plc
  • Zealand Pharma A/S
  • MORE
Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

Summary

The report ‘Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016’, provides in depth analysis on Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- The report reviews Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Naia Limited
  • Shire Plc
  • Zealand Pharma A/S
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) Overview

Therapeutics Development

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Stage of Development

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Therapy Area

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Indication

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Companies

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Companies Involved in Therapeutics Development

Naia Limited

Shire Plc

Tasly Pharmaceutical Group Co., Ltd.

Zealand Pharma A/S

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Drug Profiles

FE-203799 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-1848 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPGG-23 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPGG-72 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Dormant Projects

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Featured News & Press Releases

Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016

Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome

Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX

Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan

Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data

Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions

Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome

Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection

Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome

Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting

Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome

Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults

Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome

Dec 21, 2012: NPS Pharma's Gattex Receives FDA Approval For Treatment Of Short Bowel Syndrome

Nov 29, 2012: NPS Pharma Announces Publication Of Pivotal Phase III Study Of Gattex In Short Bowel Syndrome-intestinal Failure Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Naia Limited, H1 2016

Pipeline by Shire Plc, H1 2016

Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016

Pipeline by Zealand Pharma A/S, H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Naia Limited
  • Shire Plc
  • Zealand Pharma A/S
  • MORE
The recently published report 'Glucagon-Like Peptide 2 Receptor - Pipeline Review, H1 2016'; Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Furthermore, Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon-Like Peptide 2 Receptor - Pipeline Review, H1 2016' outlays comprehensive information on the Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively.

Note: Product cover images may vary from those shown
5 of 6
Naia Limited
Shire Plc
Tasly Pharmaceutical Group Co., Ltd.
Zealand Pharma A/S
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll